We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DexCom (DXCM) Stock Moves 0.35%: What You Should Know
Read MoreHide Full Article
In the latest trading session, DexCom (DXCM - Free Report) closed at $119.30, marking a +0.35% move from the previous day. This change outpaced the S&P 500's 0% on the day. Elsewhere, the Dow lost 0.05%, while the tech-heavy Nasdaq lost 0.21%.
Heading into today, shares of the medical device company had lost 19.38% over the past month, lagging the Medical sector's gain of 1.69% and the S&P 500's gain of 5.49% in that time.
Wall Street will be looking for positivity from DXCM as it approaches its next earnings report date. This is expected to be May 1, 2019. On that day, DXCM is projected to report earnings of -$0.17 per share, which would represent year-over-year growth of 46.88%. Our most recent consensus estimate is calling for quarterly revenue of $246.45 million, up 33.65% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $0.46 per share and revenue of $1.23 billion. These totals would mark changes of +53.33% and +19.13%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for DXCM. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. DXCM is currently sporting a Zacks Rank of #2 (Buy).
In terms of valuation, DXCM is currently trading at a Forward P/E ratio of 256.11. For comparison, its industry has an average Forward P/E of 33.45, which means DXCM is trading at a premium to the group.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 150, which puts it in the bottom 42% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DexCom (DXCM) Stock Moves 0.35%: What You Should Know
In the latest trading session, DexCom (DXCM - Free Report) closed at $119.30, marking a +0.35% move from the previous day. This change outpaced the S&P 500's 0% on the day. Elsewhere, the Dow lost 0.05%, while the tech-heavy Nasdaq lost 0.21%.
Heading into today, shares of the medical device company had lost 19.38% over the past month, lagging the Medical sector's gain of 1.69% and the S&P 500's gain of 5.49% in that time.
Wall Street will be looking for positivity from DXCM as it approaches its next earnings report date. This is expected to be May 1, 2019. On that day, DXCM is projected to report earnings of -$0.17 per share, which would represent year-over-year growth of 46.88%. Our most recent consensus estimate is calling for quarterly revenue of $246.45 million, up 33.65% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $0.46 per share and revenue of $1.23 billion. These totals would mark changes of +53.33% and +19.13%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for DXCM. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. DXCM is currently sporting a Zacks Rank of #2 (Buy).
In terms of valuation, DXCM is currently trading at a Forward P/E ratio of 256.11. For comparison, its industry has an average Forward P/E of 33.45, which means DXCM is trading at a premium to the group.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 150, which puts it in the bottom 42% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.